Financial News Feed

Weaker Buy Today URGN ranks #3 as BUY CANDIDATE. Stronger Buy
Today URGN ranks #3 as BUY CANDIDATE.

URGN stock UroGen Pharma Ltd

URGN stock
UroGen Pharma Ltd

Traders may be taking a look at the opinion signal for the last month on shares of Urogen Pharma Ltd Ordinary Shares (URGN). Looking back at the last month, the opinion signal reads 24% Buy. This is t...

Read more

Narrowing in on shares of Urogen Pharma Ltd Ordinary Shares (URGN), we can see that the current 20-Day Bollinger Bands signal is currently reading Hold. This short-term indicator can be used to help i...

Read more

Urogen Pharma Ltd Ordinary Shares (URGN) shares have reached key levels as the Elder Force Index has moved below the zero line. The Elder’s Force Index is an oscillator, which attempts to identify t...

Read more

Doing standard fundamental stock analysis is fairly straightforward. These days, investors have easy access to large amounts of available data. The biggest problem for the average investor may be dedi...

Read more

The Price to book ratio is the current share price of a company divided by the book value per share. The Price to Book ratio for Maruwa Co., Ltd. TSE:5344 is 1.406192. A lower price to book ratio indi...

Read more

The twenty one day Wilder Moving Average has been seen above the fifty day Simple Moving Average on shares of Urogen Pharma Ltd Ordinary Shares (URGN). Traders following these lines may be tracking th...

Read more

One of the biggest mistakes that can plague the individual investor is not setting up an overall investment plan. Investors may want to start out be setting up an outline of overall goals. Having goal...

Read more

The stock of Urogen Pharma LTD. – Ordinary Shares (NASDAQ:URGN) registered an increase of 8.6% in short interest. URGN’s total short interest was 486,000 shares in January as published by FINRA. I...

Read more

Investors may be focusing on technical signals for Urogen Pharma Ltd Ordinary Shares (URGN). Looking at the reading from the 20-day moving average vs price signal, we can see that the signal is showin...

Read more

UroGen Pharma Ltd’s (NASDAQ:URGN) shares climbed Wednesday in premarket trade after the biotech said its lead drug candidate UGN-101 showed positive results in a late-stage urothelial cancer study. ...

Read more

In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Urogen Pharma Ltd (URGN), with a price target of ... The post Urogen Pharma Ltd (URGN) Receives a Buy from Oppen...

Read more

In a report released yesterday, Boris Peaker from Cowen & Co. maintained a Buy rating on Urogen Pharma Ltd (URGN). The post Urogen Pharma Ltd (URGN) Gets a Buy Rating from Cowen & Co. appeared first o...

Read more

UroGen Pharma Ltd. (URGN) has an ERP5 rank of 99999. The ERP5 score was designed by the MFIE Capital team. It combines the Greenblatt Magic formula with ideas developed by Graham & Dodd, who advocated...

Read more

Studying the short-term chart on shares of Urogen Pharma Ltd Ordinary Shares (URGN), we have noted that the current 20-Day Bollinger Bands signal is presently reading Buy. This indicator may be used t...

Read more

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, today announced topline results from the ongoing pivo...

Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank